Liberia said Monday it would soon get doses of an experimental ebola drug made in the U.S. and give it to two sick doctors, making them the first Africans to receive the treatment, FoxNews reports.

The news came as anger grows in Africa over the fact that the only people to receive the experimental treatment so far have been two Americans and a Spaniard, all evacuated to their home countries from Liberia. The Americans are recovering in hospital in Atlanta. The Spaniard died.

“We can’t afford to be passive while many more die,” said Aisha Dabo, a Senegalese-Gambian journalist who tweeted using the hashtag #GiveUsTheSerum, Fox reports. “That’s why we raise our voice for the world to hear us.”

The U.S. State Department confirmed it had put the Liberian government in touch with Mapp Biopharmaceutical Inc., maker of experimental ebola drug ZMapp. The San Diego, California-based company said it has now run out of its supply of the experimental treatment.

The World Health Organization said it is ethical to use unproven, experimental drugs in the fight against ebola in West Africa.

The virus has killed 1,013 people and infected 1,848, making it the deadliest ebola outbreak in history, CNN reports. In the past, the spread of the virus was stopped by “traditional” methods — protective gear, contact tracing — but those methods aren’t working fast enough, said Dr. Marie-Paule Kieny, assistant director-general of WHO.

There was unanimous agreement this week among a panel of 12 experts that given the special circumstances of this ebola outbreak it is ethical to offer unregistered interventions as treatments or prevention, Kieny said in an AssociatedPress video.

But there are caveats, Kieny said. The panel said ethical criteria must include full transparency about all aspects of care, informed consent, freedom of choice, confidentiality, respect of person, preservation of dignity and community involvement.

Because so little is known about safety when these treatments are provided for compassionate use, it’s important to not give false hope to anybody that ebola can be treated now, she said. “This is absolutely not the case. What we rely on now is proper implementation of infection prevention and control.”

Kieny defined compassionate use as access to an unapproved drug outside a clinical trial. There is a moral obligation to collect and share all data generated, she said in the AP video.

Kentucky BioProcessing, which manufactures a version of the ZMapp drug, is working to increase production, but it will take months, company spokesman David Howard said last week, CNN reports.

“There are not adequate supplies of any of the investigational agents anywhere near ready for human use,” said Dr. Jesse Goodman, director of the Center on Medical Product Access, Safety and Stewardship at Georgetown University Medical Center, referring to all drugs being developed to treat ebola. “Not (adequate) to treat all the patients in this outbreak, even if we knew they worked.”

Some perceived the gap widening between developed and developing nations last week as reports emerged that the ebola drug was being used to treat Westerners.

“What if it had killed both of them (the Americans and the first to be treated with ZMapp)?” said Paul Root Wolpe, director of the Center for Ethics at Emory University in Atlanta. “It is only because it worked, seemingly very well, that people are screaming, ‘How come people in Africa didn’t get it?’ ”

Wolpe said some perspective was needed.

“If the first people (to receive doses of ZMapp) would have been Liberian, headlines would have screamed, ‘Experimental drug tested on poor Africans,'” Wolpe said.

Some are asking whether giving the serum to Africans was even a consideration, CNN reports. Should it have been?

“Why didn’t Dr. Sheik Umar Khan, the chief Sierra Leone physician who died while treating ebola patients, receive this medication?” Harriet Washington wrote in a recent CNN Opinion piece. “Because another method of determining who gets medications is at work here — the drearily familiar stratification of access to a drug based on economic resources and being a Westerner rather than a resident of the global South.”

Other Ebola drugs are currently being tested including TKM-Ebola by Tekmira Pharmaceuticals in Canada.

The U.S. State Department on Tuesday issued a Response to the Ebola Virus Fact Sheet saying the U.S. government is working with WHO and other international partners to help West African governments respond to and contain the outbreak.

The full range of relevant U.S. government agencies include the State Department, Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention (CDC), U.S. Agency for International Development (USAID), and the Department of Defense (DOD).

U.S. assistance includes equipment and other essential supplies, public health messaging efforts, and technical and medical expertise.

The U.S. State Department issued a travel warning Aug.  7 against non-essential travel to Liberia and ordered family members living with U.S. Embassy staff in Monrovia to begin leaving the country Aug. 8 due to a lack of options for routine health care services.

U.S. government employees in Liberia will stay on active duty at the embassy and additional staff members are being deployed to help the government of Liberia address the ebola virus.

No ebola-related travel restrictions have been issued by the State Department for Guinea, Nigeria, or Sierra Leone. However, CDC has issued alerts for the four countries with Level 3 warnings for Guinea, Liberia and Sierra Leone and Level 2 for Nigeria.

U.S. embassies remain open and will continue business as usual in Guinea, Liberia, Nigeria, and Sierra Leone, the statement said.

You can find the latest U.S. government information on warnings and alerts here.